MX2021003510A - Formulaciones mezcladas. - Google Patents
Formulaciones mezcladas.Info
- Publication number
- MX2021003510A MX2021003510A MX2021003510A MX2021003510A MX2021003510A MX 2021003510 A MX2021003510 A MX 2021003510A MX 2021003510 A MX2021003510 A MX 2021003510A MX 2021003510 A MX2021003510 A MX 2021003510A MX 2021003510 A MX2021003510 A MX 2021003510A
- Authority
- MX
- Mexico
- Prior art keywords
- formulation
- colloidal particles
- aoi
- present
- deformable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/618—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/14—Liposomes; Vesicles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
Abstract
La presente invención se refiere a una formulación que comprende mezclas de formulaciones (o dispersiones coloidales) y su aplicación tópica. La formulación comprende al menos dos tipos diferentes de dispersión coloidal que comprenden partículas coloidales deformables, en donde las partículas coloidales deformables comprenden un tensioactivo no iónico y / o un fosfolípido. Las partículas coloidales deformables de la invención pueden comprender un agente de interés (AOI) o pueden estar libres de un AOI. La formulación puede comprender un AOI que no está asociado con las partículas coloidales deformables. La presente invención también incluye kits que comprenden la formulación de la presente invención y el uso de la formulación en medicina, cuidado de la piel y cosméticos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1511469.7A GB201511469D0 (en) | 2015-06-30 | 2015-06-30 | Compositions |
GBGB1511478.8A GB201511478D0 (en) | 2015-06-30 | 2015-06-30 | Blended formulations |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021003510A true MX2021003510A (es) | 2021-05-27 |
Family
ID=56292753
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018000024A MX2018000024A (es) | 2015-06-30 | 2016-06-30 | Formulaciones mezcladas. |
MX2021004766A MX2021004766A (es) | 2015-06-30 | 2016-06-30 | Composiciones multifásicas. |
MX2018000021A MX2018000021A (es) | 2015-06-30 | 2016-06-30 | Composiciones multifasicas. |
MX2021003510A MX2021003510A (es) | 2015-06-30 | 2017-12-20 | Formulaciones mezcladas. |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018000024A MX2018000024A (es) | 2015-06-30 | 2016-06-30 | Formulaciones mezcladas. |
MX2021004766A MX2021004766A (es) | 2015-06-30 | 2016-06-30 | Composiciones multifásicas. |
MX2018000021A MX2018000021A (es) | 2015-06-30 | 2016-06-30 | Composiciones multifasicas. |
Country Status (15)
Country | Link |
---|---|
US (5) | US10744090B2 (es) |
EP (3) | EP3316856B1 (es) |
JP (2) | JP6851998B2 (es) |
CA (2) | CA3026466A1 (es) |
DK (2) | DK3316856T3 (es) |
EA (2) | EA038208B1 (es) |
ES (2) | ES2879383T3 (es) |
HK (2) | HK1254979A1 (es) |
HR (2) | HRP20211669T1 (es) |
HU (2) | HUE056161T2 (es) |
LT (2) | LT3316856T (es) |
MX (4) | MX2018000024A (es) |
PL (2) | PL3316857T3 (es) |
PT (2) | PT3316857T (es) |
WO (2) | WO2017001625A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3316856B1 (en) | 2015-06-30 | 2021-04-07 | Sequessome Technology Holdings Limited | Blended formulations |
US10086035B2 (en) | 2016-02-04 | 2018-10-02 | ALASTIN Skincare, Inc. | Compositions and methods for invasive and non-invasive procedural skincare |
US10493011B2 (en) | 2017-08-03 | 2019-12-03 | ALASTIN Skincare, Inc. | Peptide compositions and methods for ameliorating skin laxity and body contour |
EP4324460A3 (en) | 2017-09-15 | 2024-04-24 | Dyve Biosciences, Inc. | Sodium bicarbonate for use in the treatment of gout and related disorders |
WO2020028694A1 (en) | 2018-08-02 | 2020-02-06 | ALASTIN Skincare, Inc. | Liposomal compositions and methods of use |
Family Cites Families (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4372296A (en) | 1980-11-26 | 1983-02-08 | Fahim Mostafa S | Treatment of acne and skin disorders and compositions therefor |
JPS60136511A (ja) | 1983-12-26 | 1985-07-20 | Eisai Co Ltd | 高尿酸血症治療剤 |
JPS63501289A (ja) | 1985-09-27 | 1988-05-19 | ザ リ−ジエンツ オブ ザ ユニバ−シテイ オブ カリフオルニア | リポソ−ム経皮薬剤供給系 |
JPS6295134A (ja) | 1985-10-21 | 1987-05-01 | Nippon Saafuakutanto Kogyo Kk | リポソ−ムの製造法 |
US5015483A (en) | 1989-02-09 | 1991-05-14 | Nabisco Brands, Inc. | Liposome composition for the stabilization of oxidizable substances |
US5498607A (en) | 1990-07-30 | 1996-03-12 | University Of Miami | Treatment for hypercholesterolemia |
US6165500A (en) | 1990-08-24 | 2000-12-26 | Idea Ag | Preparation for the application of agents in mini-droplets |
CA2067754C (en) | 1990-08-24 | 2002-06-04 | Gregor Cevc | Preparation for the application of agents in mini-droplets |
US5498420A (en) | 1991-04-12 | 1996-03-12 | Merz & Co. Gmbh & Co. | Stable small particle liposome preparations, their production and use in topical cosmetic, and pharmaceutical compositions |
CA2139757C (en) | 1992-07-08 | 2009-04-14 | Gunther Maierhofer | Liposomes, method of preparing the same and use thereof in the preparation of drugs |
FR2714382B1 (fr) | 1993-12-27 | 1996-02-02 | Roussel Uclaf | Phospholipides vecteur de molécule active, leur préparation et leur utilisation dans des compositions cosmétiques ou dermatologiques. |
FR2714596B1 (fr) * | 1993-12-30 | 1996-02-09 | Oreal | Composition cosmétique pour le traitement simultané des couches superficielles et profondes de la peau, son utilisation. |
US5942245A (en) | 1994-11-04 | 1999-08-24 | Polymun Scientific Immunbiologische Forschung Gmbh | Application of SOD in liposomes |
DE4447287C1 (de) | 1994-12-30 | 1996-11-07 | Cevc Gregor | Präparat zum Wirkstofftransport durch Barrieren |
US5902604A (en) | 1995-06-06 | 1999-05-11 | Board Of Regents, The University Of Texas System | Submicron liposome suspensions obtained from preliposome lyophilizates |
FR2767691B1 (fr) | 1997-08-27 | 2000-02-18 | Oreal | Utilisation d'une dispersion a base de vehicules lipidiques comme composition anti-inflammatoire |
IL122084A (en) * | 1997-10-31 | 1999-09-22 | Lurident Ltd | Formulation for personal care with mucoadhesive properties |
DE59802473D1 (de) | 1997-11-19 | 2002-01-24 | Schering Ag | Zusammensetzung mit azelainsäure |
US6165997A (en) | 1997-11-20 | 2000-12-26 | Statens Serum Institut | Phospholipids having antimicrobial activity with or without the presence of antimicrobials |
CA2283574A1 (en) * | 1998-01-16 | 1999-07-22 | Color Access, Inc. | Stabilized whitening compositions and method of preparing same |
EP1107729A1 (en) | 1998-09-01 | 2001-06-20 | Idea Ag | Electrically controlled transport of charged penetrants across barriers |
NZ332905A (en) | 1998-11-19 | 2000-12-22 | Immuno Lab Ltd | Transdermal pharmaceutical composition comprising liposomal bee venom |
PL193824B1 (pl) | 1998-12-23 | 2007-03-30 | Idea Ag | Preparat zawierający środki penetrujące, sposób wytwarzania preparatu zawierającego środki penetrujące oraz zastosowanie preparatu do wytwarzania leku |
EP1031346B1 (en) | 1999-01-27 | 2002-05-02 | Idea Ag | Noninvasive vaccination through the skin |
GB9902527D0 (en) | 1999-02-04 | 1999-03-24 | Phares Pharm Res Nv | Compositions |
US6294192B1 (en) | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
MXPA02000053A (es) | 1999-07-05 | 2003-07-21 | Idea Ag | Un metodo para mejorar el tratamiento a traves de barreras adaptables semipermeables. |
US6248728B1 (en) | 2000-03-10 | 2001-06-19 | Kansas State University Research Foundation | Phosphatidylcholine compositions and methods for lowering intestinal absorption and plasma levels of cholesterol |
US6191121B1 (en) | 2000-04-06 | 2001-02-20 | Nicholas V. Perricone | Treatment of skin damage using polyenylphosphatidylcholine |
DE60122304T2 (de) | 2000-04-12 | 2007-08-09 | Liplasome Pharma A/S | Auf lipiden basierendes system zur zielgerichteten verabreichung diagnostischer wirkstoffe |
TWI281407B (en) | 2000-09-18 | 2007-05-21 | Vasogen Ireland Ltd | Apoptosis-mimicking synthetic entities and use thereof in medical treatment |
US20030064948A1 (en) | 2001-02-08 | 2003-04-03 | Alfred Fahr | Invasomes for therapy of disorders, their preparation and use |
JP2004532871A (ja) | 2001-05-31 | 2004-10-28 | ファルマシア・コーポレーション | 皮膚浸透性シクロオキシゲナーゼ−2選択的阻害組成物 |
WO2003000190A2 (en) | 2001-06-25 | 2003-01-03 | Depuy | Liposomal encapsulation of glycosaminoglycans for the treatment of arthritic joints |
CA2368656A1 (en) | 2002-01-21 | 2003-07-21 | Vasogen Ireland Limited | Receptor-ligand pairing for anti-inflammatory response |
ES2411656T3 (es) | 2002-03-13 | 2013-07-08 | Thomas SKÖLD | Sistemas de administración a base de agua |
JP3851312B2 (ja) * | 2002-04-22 | 2006-11-29 | ザ プロクター アンド ギャンブル カンパニー | 水性界面活性剤組成物中に亜鉛含有物質を含むパーソナルケア組成物 |
US20040009180A1 (en) | 2002-07-11 | 2004-01-15 | Allergan, Inc. | Transdermal botulinum toxin compositions |
JP2004131432A (ja) | 2002-10-11 | 2004-04-30 | Kumamoto Technology & Industry Foundation | 悪性腫瘍抑制剤 |
DK1551370T3 (da) | 2002-10-11 | 2008-03-03 | Idea Ag | Aggregat med foröget deformerbarhed, som omfatter mindst tre amfipater, til forbedret transport gennem semipermeable barrierer og til ikke-invasiv lægemiddeltilförsel in vivo, især gennem huden |
US7473432B2 (en) | 2002-10-11 | 2009-01-06 | Idea Ag | NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery |
AU2004235781A1 (en) | 2003-05-02 | 2004-11-18 | Aronex Pharmaceuticals, Inc. | Lipid platinum complexes and methods of use thereof |
EP1514539A3 (en) * | 2003-05-14 | 2005-05-04 | Signal Investment & Management Co. | Micro-encapsulated topical analgesic for pain relief and sleeve comprising it |
KR20060037369A (ko) | 2003-07-21 | 2006-05-03 | 바소겐 아일랜드 리미티드 | 급성 염증 상태의 치료를 위한 포스페이트 글리세롤 기를함유하는 리포솜 |
JP2005179313A (ja) | 2003-12-24 | 2005-07-07 | Shu Uemura:Kk | 皮膚化粧料用基剤の製造方法および皮膚化粧料 |
US7476432B2 (en) | 2004-05-28 | 2009-01-13 | Tecton Products | Phosphorescent pultrusion |
CA2584475A1 (en) | 2004-11-12 | 2006-05-18 | Idea Ag | Extended surface aggregates in the treatment of skin conditions |
WO2006086992A2 (en) | 2005-02-18 | 2006-08-24 | Liplasome Pharma A/S | Drug delivery systems containing phqspholipase a2 degradable lipid prodrug derivatives and the therapeutic uses thereof as. e.g. wound healing agents and peroxisome proliferator activated receptor ligands |
US20070042008A1 (en) | 2005-08-18 | 2007-02-22 | Bodybio, Inc. | Compositions containing phosphatidylcholine and essential fatty acids |
AP2626A (en) | 2005-08-29 | 2013-03-26 | Sepsicure Llc | Method for treatment or prevention of conditions caused by gram-positive bacteria |
TWI387592B (zh) | 2005-08-30 | 2013-03-01 | Novartis Ag | 經取代之苯并咪唑及其作為與腫瘤形成相關激酶之抑制劑之方法 |
EP2364701A1 (en) | 2005-12-20 | 2011-09-14 | Cenestra, Llc | Omega-3 fatty acid formulations |
JP5009547B2 (ja) | 2006-03-31 | 2012-08-22 | 株式会社コーセー | 顔料とリポソームを含む化粧料 |
US7544375B1 (en) | 2006-06-12 | 2009-06-09 | Swiss Skin Repair, Inc. | Composition |
WO2008039989A2 (en) * | 2006-09-28 | 2008-04-03 | Transave, Inc. | Formulations of dnase and methods of use thereof |
EP2079442B1 (en) | 2006-09-28 | 2016-07-27 | Hadasit Medical Research Services & Development Limited | Use of glycerophospholipids for joint lubrication |
JP4732307B2 (ja) | 2006-11-20 | 2011-07-27 | 株式会社アンズコーポレーション | ナノエマルション及びそれを配合した化粧料 |
US20100130611A1 (en) | 2006-12-20 | 2010-05-27 | Cenestra Llc | Omega 3 fatty acid formulations |
EP1938801A1 (en) | 2006-12-22 | 2008-07-02 | Biofrontera Bioscience GmbH | Nanoemulsion |
US9511016B2 (en) | 2007-06-12 | 2016-12-06 | Epicentrx, Inc. | Topical composition for treating pain |
ITVR20080006A1 (it) | 2008-01-23 | 2009-07-24 | David Ceretta | Apparato per la realizzazione di elementi d'impasto |
ES2335636B1 (es) * | 2008-02-29 | 2011-05-11 | Lipotec, S.A. | Composicion cosmetica o dermofarmaceutica de micelas mixtas. |
JP2009256331A (ja) | 2008-03-25 | 2009-11-05 | Nagase Chemtex Corp | 高尿酸血症、又は痛風の予防、改善、又は治療剤 |
US20100105139A1 (en) | 2008-10-27 | 2010-04-29 | Remco Alexander Spanjaard | Ligand Targeted Nanocapsules for the delivery of RNAi and other Agents |
JP2012516889A (ja) | 2009-02-05 | 2012-07-26 | ターゲッティド デリバリー テクノロジーズ リミテッド | 微生物因子の増殖及び生存能力を低下させる方法 |
NZ597419A (en) | 2009-06-03 | 2014-01-31 | John Charles Mayo | Formulations for the treatment of deep tissue pain |
JP2013502436A (ja) | 2009-08-21 | 2013-01-24 | ターゲッティド デリバリー テクノロジーズ リミテッド | 小胞状の製剤 |
EP2382994A1 (en) | 2010-04-26 | 2011-11-02 | Maurizio Victor Cattaneo | Ligand targeted nanocapsules for the delivery of RNAi and other agents |
WO2011162802A1 (en) | 2010-06-21 | 2011-12-29 | Virun, Inc. | Compositions containing non-polar compounds |
US20120045405A1 (en) | 2010-08-18 | 2012-02-23 | Gilman Miles E | Under eye cream |
US20120294924A1 (en) | 2011-04-29 | 2012-11-22 | Thomas Tice | Peptide-Lipid Conjugates And Uses Thereof |
GB201205642D0 (en) | 2012-03-29 | 2012-05-16 | Sequessome Technology Holdings Ltd | Vesicular formulations |
GB201206486D0 (en) | 2012-04-12 | 2012-05-30 | Sequessome Technology Holdings Ltd | Vesicular formulations and uses thereof |
GB201208409D0 (en) | 2012-05-14 | 2012-06-27 | Sequessome Technology Holdings Ltd | Vesicular formulations, kits and uses |
GB201208384D0 (en) | 2012-05-14 | 2012-06-27 | Sequessome Technology Holdings Ltd | Vesicular formulations, uses and methods |
EP3027219A1 (en) | 2013-07-31 | 2016-06-08 | Sequessome Technology Holdings Limited | Vesicles |
EP3316856B1 (en) | 2015-06-30 | 2021-04-07 | Sequessome Technology Holdings Limited | Blended formulations |
CA3142730A1 (en) * | 2019-06-04 | 2020-12-10 | Aquavit Pharmaceuticals, Inc. | Methods and compositions for microflillng the skin with hyaluronic acid using microchannel technology |
-
2016
- 2016-06-30 EP EP16733592.6A patent/EP3316856B1/en active Active
- 2016-06-30 EP EP21189470.4A patent/EP3954361A1/en active Pending
- 2016-06-30 DK DK16733592.6T patent/DK3316856T3/da active
- 2016-06-30 EP EP16733595.9A patent/EP3316857B1/en active Active
- 2016-06-30 EA EA201890120A patent/EA038208B1/ru unknown
- 2016-06-30 DK DK16733595.9T patent/DK3316857T3/da active
- 2016-06-30 LT LTEP16733592.6T patent/LT3316856T/lt unknown
- 2016-06-30 MX MX2018000024A patent/MX2018000024A/es unknown
- 2016-06-30 MX MX2021004766A patent/MX2021004766A/es unknown
- 2016-06-30 CA CA3026466A patent/CA3026466A1/en active Pending
- 2016-06-30 PL PL16733595T patent/PL3316857T3/pl unknown
- 2016-06-30 ES ES16733592T patent/ES2879383T3/es active Active
- 2016-06-30 MX MX2018000021A patent/MX2018000021A/es unknown
- 2016-06-30 PL PL16733592T patent/PL3316856T3/pl unknown
- 2016-06-30 JP JP2017568160A patent/JP6851998B2/ja active Active
- 2016-06-30 WO PCT/EP2016/065425 patent/WO2017001625A1/en active Application Filing
- 2016-06-30 CA CA3026484A patent/CA3026484A1/en active Pending
- 2016-06-30 US US15/739,575 patent/US10744090B2/en active Active
- 2016-06-30 ES ES16733595T patent/ES2895910T3/es active Active
- 2016-06-30 WO PCT/EP2016/065415 patent/WO2017001617A1/en active Application Filing
- 2016-06-30 HU HUE16733595A patent/HUE056161T2/hu unknown
- 2016-06-30 PT PT167335959T patent/PT3316857T/pt unknown
- 2016-06-30 HU HUE16733592A patent/HUE054749T2/hu unknown
- 2016-06-30 HR HRP20211669TT patent/HRP20211669T1/hr unknown
- 2016-06-30 PT PT167335926T patent/PT3316856T/pt unknown
- 2016-06-30 EA EA201890119A patent/EA038613B1/ru unknown
- 2016-06-30 US US15/739,570 patent/US20190167588A1/en not_active Abandoned
- 2016-06-30 LT LTEPPCT/EP2016/065425T patent/LT3316857T/lt unknown
-
2017
- 2017-12-20 MX MX2021003510A patent/MX2021003510A/es unknown
-
2018
- 2018-11-05 HK HK18114088.4A patent/HK1254979A1/zh unknown
- 2018-11-05 HK HK18114089.3A patent/HK1254980A1/zh unknown
-
2020
- 2020-07-08 US US16/923,810 patent/US20220370353A9/en not_active Abandoned
- 2020-07-14 US US16/929,009 patent/US11547665B2/en active Active
-
2021
- 2021-03-10 JP JP2021038221A patent/JP2021091730A/ja active Pending
- 2021-06-07 HR HRP20210903TT patent/HRP20210903T1/hr unknown
-
2023
- 2023-10-19 US US18/490,255 patent/US20240099976A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021003510A (es) | Formulaciones mezcladas. | |
MX2018009824A (es) | Composiciones para el cuidado personal. | |
BR112015030649A2 (pt) | sanitizante a base de álcool com sensação e compatibilidade dérmica melhoradas | |
BR112017022021A2 (pt) | aplicação de agente anticaspa solúvel em tensoativo | |
WO2018115097A9 (en) | Ophthalmic composition for treatment of dry eye disease | |
EP3686184A3 (en) | Ionizable compounds and compositions and uses thereof | |
BR112015003963A2 (pt) | dispersões de cera aquosas e composições de modelação do cabelo contendo as mesmas | |
EP3151923A4 (en) | Clear compositions and methods for the delivery of active ingredients for skin care | |
PH12017500098A1 (en) | Suspension compositions of cyclosporin a for subconjunctival and periocular injection | |
MX2019008544A (es) | Nueva formulacion estable para anticuerpos anti-fxia. | |
MX2019005925A (es) | Composiciones de alergenos liquidas y metodos para la preparacion de las mismas. | |
BR112015028499A2 (pt) | Peptídeo para induzir apoptose específica de mastócito e uso do mesmo | |
BR112018010945A2 (pt) | formulações com degradação de polissorbato reduzida | |
BR112016029278A2 (pt) | composição cosmética compreendendo um polímero espessante que tem porções hidrofóbicas e hidrofílicas | |
MX2020005056A (es) | Emulsiones para el tratamiento tópico de infecciones dérmicas y de mucosas. | |
BR112017025043A2 (pt) | formulação para cuidado dos cabelos | |
WO2016113752A3 (en) | Liquid formulation of cabazitaxel | |
MX2019003212A (es) | Composiciones que comprenden tensioactivos especificos y altos niveles de glicerina. | |
BR112015032449A2 (pt) | composição e processo em particular para o cuidado, a limpeza e/ou o condicionamento das matérias queratínicas | |
WO2017142368A3 (ko) | 알레르기성 또는 염증성 피부질환의 예방 또는 치료용 조성물 | |
EA202191803A3 (ru) | Смешанные составы | |
MY197938A (en) | Cosmetic composition of dispersion formulation comprising spherical particle | |
BR112017013208A2 (pt) | uso de octenidina | |
PL414021A1 (pl) | Formulacja farmaceutyczna zawierająca izotiocyjaniany i doksorubicynę do zastosowania w leczeniu nowotworów | |
WO2013140153A3 (en) | Cosmetic and pharmaceutical uses of saccharides |